Wall Street Not Ready To Go Out On A Limb For Xoma/Genetech Xanelim
Executive Summary
Investors appear to be taking a wait-and-see attitude toward Xoma/Genetech's anti-CD11a humanized monoclonal antibody Xanelim, now in Phase III for psoriasis.
You may also be interested in...
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.